Neurelis Reports Transformational Growth with VALTOCO Expansion and Patent Extensions Through 2032
核心洞察
Neurelis (搜索) achieved estimated net sales of $295-300 million for 2025, more than doubling 2024 revenue, with EBITDA margins exceeding 30%.
The FDA approved VALTOCO (搜索) label expansion for children ages 2-5, with over 12,000 young patients already prescribed the seizure treatment.
Three new patents extend VALTOCO (搜索) market exclusivity through October 2032, strengthening the company's intellectual property portfolio to six total patents.
Neurelis (搜索), Inc. reported remarkable financial and regulatory achievements for 2025, with the epilepsy-focused neuroscience company achieving estimated net sales of $295-300 million and EBITDA margins exceeding 30%. The company's flagship product VALTOCO (搜索) (diazepam nasal spray) drove this transformational growth following FDA approval for expanded use in younger pediatric patients and strengthened patent protection extending through 2032.
FDA Label Expansion Drives Pediatric Adoption
The FDA approved expansion of VALTOCO (搜索)'s indication to include treatment of seizure clusters in children ages 2 to 5 years old. This regulatory milestone has already resulted in over 12,000 patients in this younger age group being prescribed VALTOCO. The intranasal formulation was previously recognized by the FDA as clinically superior to rectal gel diazepam formulations in patients ages 6 and above, earning orphan drug exclusivity designation.
"The label expansion granted by the FDA for VALTOCO (搜索) reflects the safety and effectiveness of this product by extending the clinical benefits to an even younger patient population," said Craig Chambliss, Neurelis (搜索) Co-Founder and CEO. "The tremendous growth of VALTOCO in 2025 is significant progress in ensuring patients have an immediate-use seizure treatment when and where they need it."
Patent Portfolio Strengthens Market Position
Neurelis (搜索) secured three additional U.S. patents for VALTOCO (搜索), bringing the total Orange Book-listed patents to six. The newly issued Patents No. 12,324,852 and No. 12,337,061 cover methods of treating acute seizure clusters with intranasal diazepam administration and extend patent protection through October 2032. These patents demonstrate significant clinical benefits including reduction in seizure severity, frequency, and probability of recurrence, with rapid treatment onset and duration lasting up to 24 hours.
The expanded intellectual property estate reinforces VALTOCO (搜索)'s distinct therapeutic value in treating episodic frequent seizures in epilepsy patients and provides extended market exclusivity for the company's commercial efforts.
Commercial Enhancements Address Clinical Needs
Following an independent prescription audit in 2024 that revealed discrepancies between prescribed and dispensed medication amounts, Neurelis (搜索) introduced new five-dose retail packaging for VALTOCO (搜索). This packaging enhancement ensures patients receive the number of doses intended by their healthcare provider while remaining within FDA-approved labeling parameters of treating up to five seizure episodes per month with a maximum of ten doses monthly.
The company maintained pricing stability with no change in per-dose costs and preserved existing managed care coverage. Additionally, VALTOCO (搜索)'s shelf life was extended to 32-36 months, improving product accessibility.
Strong Financial Foundation Supports Pipeline Development
Neurelis (搜索) reported a robust balance sheet with no bank debt and cash reserves exceeding $175 million as of December 31, 2025. This financial strength positions the company to advance its CNS-focused pipeline, which includes NRL-1004, an investigational Phase 1 intranasal olanzapine for acute agitation episodes in schizophrenia and bipolar disorder, and NRL-1049, a Phase 1 Rho kinase (ROCK) inhibitor for cerebral cavernous malformations.
"Neurelis (搜索) is in a stronger position than ever, with a sound financial foundation and cash flow generation, to continue advancing CNS-focused treatments that address unmet needs and empower providers and patients," Chambliss stated.
VALTOCO (搜索) incorporates INTRAVAIL transmucosal absorption enhancement technology, enabling noninvasive delivery of the diazepam formulation. The treatment is indicated for acute management of intermittent, stereotypic episodes of frequent seizure activity distinct from patients' usual seizure patterns in individuals with epilepsy aged 2 years and older.